Residual Renal Risk in Diabetic Nephropathy Despite Contemporary Therapies
Journal of Clinical Medicine · 23.01.2026 · 15 (3) · 921
DOI: 10.3390/jcm15030921 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 23.01.2026. Verfasst von Reinhart Speeckaert und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Ghent University Hospital, 9000 Ghent, Belgium. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Diabetic kidney disease (DKD) is the most prevalent form of chronic kidney disease and kidney failure globally. In the last decade, RAAS inhibitors, SGLT2 inhibitors, GLP-1-receptor agonists, and non-steroidal mineralocorticoid receptor antagonists have made significant advancements. However, despite the use of these drugs, patients with DKD often show a residual renal risk. In this narrative review, we synthesize current evidence on residual renal risk in DKD, focusing on underlying mechanisms, high-risk clinical phenotypes, and therapeutic gaps.
Methods
A narrative review of current literature available in clinical trials, post hoc analysis studies, observational studies, and research into mechanisms of action or processes related to DKD was performed.
Results
The central element of residual renal risk in DKD is persistent inflammation, fibrosis, tubulointerstitial injury/injury to both renal and vascular systems, and metabolic memory. These represent the four types of renal-related problems that have been identified. Non-albuminuric DKD, rapid progressors, late presenters with multiple comorbidities, tend to exhibit an extreme burden associated with some of these entities.
Conclusions
The remaining risk factors that cannot be adequately addressed by current medical treatments represent major opportunities for improved clinical management, i.e., those at high-risk of kidney failure. Future research initiatives are required to further refine and improve therapeutic approaches for early intervention in patients with DKD. In addition, development of specific treatments targeting inflammation, fibrosis and metabolism in the kidney will lead to better therapeutic results and decreased risk of progressive loss of kidney function.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Ghent University Hospital, 9000 Ghent, Belgium.
- Department of Nephrology, Ghent University Hospital, 9000 Ghent, Belgium.
- Research Foundation-Flanders (FWO), 1000 Brussels, Belgium.
ORCID-Profile: Reinhart Speeckaert, Marijn M Speeckaert
Zitieren
APA
Speeckaert, R., Delrue, C., & Speeckaert, M. M. (2026). Residual Renal Risk in Diabetic Nephropathy Despite Contemporary Therapies. Journal of Clinical Medicine, 15(3), 921. https://doi.org/10.3390/jcm15030921
Vancouver
Speeckaert R, Delrue C, Speeckaert MM. Residual Renal Risk in Diabetic Nephropathy Despite Contemporary Therapies. Journal of Clinical Medicine. 2026;15(3):921. doi:10.3390/jcm15030921
BibTeX
@article{Speeckaert2026,
author = {Speeckaert, Reinhart and Delrue, Charlotte and Speeckaert, Marijn M},
title = {Residual Renal Risk in Diabetic Nephropathy Despite Contemporary Therapies},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {3},
pages = {921},
doi = {10.3390/jcm15030921}
}
EUVIMED